News | January 11, 2026
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The approval is backed by data showing deep, durable responses and manageable tolerability
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Subscribe To Our Newsletter & Stay Updated
